Biliary Atresia: How do we better understand pathways and disease progression?

Description

The Ipsen-sponsored TLM Theatre will explore current approaches to the management of Biliary Atresia, highlighting opportunities for further optimization of care and patient outcomes. Prognostic biomarkers and the underlying pathophysiology driving disease progression in Biliary Atresia will also be addressed.

Industry Supporter: Ipsen Biopharmaceuticals